Healthcare / Medical DevicesNasdaqGS
$1.12
+0.02 (+1.82%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-29.3M · quality 78.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$120M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-26.0%
↓Gross Margin
81.2%
↑Debt/Equity
0.10
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
+16.4%
FCF CAGR
—
FCF margin
-109.5%
FCF / Net income
0.81x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $33.0M · net income $-44.6M · FCF $-36.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $33.0M | $33.0M | $38.6M | $41.3M | $44.3M | $21.6M | $15.5M | $13.3M |
| Net Income | $-44.6M | $-44.6M | $-41.1M | $-37.9M | $-23.6M | $-19.1M | $-11.8M | $-12.9M |
| EBITDA | $-40.1M | $-40.1M | $-46.4M | $-43.7M | $-24.7M | $-16.8M | $-10.0M | $-11.8M |
| EPS | -0.42 | -0.42 | -0.39 | -0.37 | -0.23 | -0.21 | -0.17 | -0.23 |
| Gross Margin | 81.2% | 81.2% | 81.6% | 88.5% | 88.5% | 140.2% | 151.5% | 144.2% |
| Operating Margin | -137.1% | -137.1% | -132.5% | -117.0% | -61.8% | -84.3% | -71.6% | -93.7% |
| Net Margin | -135.1% | -135.1% | -106.3% | -91.8% | -53.3% | -88.5% | -76.5% | -97.3% |
| Balance Sheet | ||||||||
| Debt/Equity | 0.10 | 0.10 | 0.09 | 0.08 | 0.06 | — | — | — |
| Current Ratio | 12.04 | 12.04 | — | — | — | — | — | — |
| Cash Flow | ||||||||
| Free Cash Flow | $-36.2M | $-36.2M | $-29.3M | $-25.4M | $-33.3M | $-14.5M | $-10.9M | $-10.1M |
| Returns | ||||||||
| ROE | -26.0% | -26.0% | -19.9% | -16.3% | -9.3% | -7.3% | -35.6% | -94.8% |
| Valuation | ||||||||
| P/B | 0.70 | 0.70 | 2.23 | 2.05 | 2.09 | — | — | — |
| Growth & Yield | ||||||||
| Revenue Growth | -14.5% | -14.5% | -6.4% | -6.7% | — | 39.6% | 16.6% | — |
| EPS Growth | -7.7% | -7.7% | -5.4% | -60.9% | — | -23.5% | 26.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-50.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.39 → -0.42
Residual
-50.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.